Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Aside from the uncertainty this is creating is there a penalty for not publishing your year end financial results in line with the AIM rules (apart from deterring future investors and upsetting existing ones)?
So where are the bl00dy results? This is incompetence and confidence-sapping in the extreme. It all looked good after the settlement but it is all about trust and communication and delivery in markets. A big black mark for the CEO I’m afraid.
Don’t we have a commercial guy already, is it Peter Collins?
This must be a bit of a blow to TF though that they will inevitably sell no sequencers through Premaitha in not only the UK but also 15 other European countries? I’m sure they were expecting only UK not Europe as well? It seems to me a bad deal for TF, which is perhaps why it has taken so long to negotiate? I accept there is more growth outside Europe but nonetheless they would have preferred the loss to be only the UK. Perhaps we will have both Illumina and TF fighting to take us over one day! I would have liked a statement about the relationship with TF, even it was just a bland, general one.
Great news today and much progress to be happy about. I am amazed the share price did not double though! The RNS was silent on a few key questions: How much will it cost to migrate existing customers to the Illumina platform and who will pay for it? How many customers will we lose? What are the implications of this deal for the relationship with TF and any future takeover? What are the legal fees we have incurred to resolve this that have not yet been disclosed? Is it included in the £1m? What will the license fee be per test? What are the costs of running two platforms? Does the new addressable market include the US? Good luck everyone and I hope I will reach my breakeven of 16p very soon!
It’s September and we’re still waiting for y/e March results. Still it has to be in the next four working weeks!
I doubt it. I can’t believe they will announce any disposal so soon after awarding share options. If they do it would seem dreadful corporate governance and perhaps reportable. But then nothing would surprise me with this Board. I think a disposal is some time away but we may get news on the further workstreams taking place on Eureka and Mankayan.
I think this test is being offered in the UK not Germany although it is a German company. Good news companies are still opening in the UK to offer the test. Does anyone know if other companies or NHS Trusts have pre-natal testing recently, whether from us the competition?
I agree totally. These share options today are just two fingers to shareholders and tell me that we are some way from a disposal if at all but the directors are getting shares at a ridiculously low price with no risk. If it had been 1p for both tranches as someone said I would be ok with it. This lot have proved themselves to be utterly useless. They have achieved nothing in years. And now they are slimy golddiggers as well. I agree a shareholder action group is called for. We are going nowhere right now.
It actually seems to be worth nothing at the moment because no one wants to buy it. Are we dreaming about a sale or is it realistic? Gold Fields don’t seem to be doing anything with Far South East unless I am missing something?
If this cretin Bird and his useless sidekick Read are fixated on 250m we are doomed. I would accept the 75m Gold Fields offered to be honest and even then we would have got out of jail free. This needs a line drawing under it quickly now before we sink into oblivion.
Great article in the FT this weekend about the looming copper supply crunch given the demand for renewable energy and electric vehicles and the consequent need to focus on mining in challenging, volatile countries such as Mongolia.
It should be like selling ice cream in hot weather to dispose of Mankayan in this environment.